Datapoint: Pfizer Scores Endometriosis Nod for Myfembree

The FDA last week approved Pfizer’s Myfembree for the treatment of moderate to severe endometriosis pain in pre-menopausal women. The once-daily pill was first approved for the treatment of uterine fibroids in May 2021. For this indication, the drug currently holds covered or better status for 80% of all insured lives, with 44.8% having preferred access to Myfembree.

SOURCE: MMIT Analytics, as of 8/10/22

0

0

0 Comments

0

0

• Datapoint